Adagio Files $100M IPO To Take Its COVID-19 Antibody Through Commercialization In 2022

  • Adagio Therapeutics has filed an initial public offering to raise money to bring its COVID-19 antibody to market. 
  • The $100 million IPO will support Phase 2/3 trials that CEO Tillman Gerngross’ Adagio is running to position ADG20 to treat and prevent COVID-19.
  • Adimab-spinout Adagio has succeeded in attracting investor support for its anti-SARS-CoV-2 antibody even as rival assets have come to market and vaccines have curbed the crisis in some countries.
  • In April, the Company raised a $336 million Series C round of funding.
  • Adagio has taken ADG20 into phase 2/3 treatment and prevention clinical trials on the strength of early-phase data. The treatment trial, called STAMP, enrolls mild-to-moderate COVID-19 patients at high risk of disease progression to generate data to support the commercial launch in 2022.
  • The IPO paperwork reveals Adagio modified the design and conduct of the STAMP trial “exclusively outside of the United States” after the FDA said, “it had changed its view on allowing high-risk patients to be randomized to placebo.” Adagio now intends to conduct its STAMP treatment trial at sites outside the U.S., provided overseas regulators support its plans. 
  • Adagio is 31% owned by Adimab, a privately held company that licenses its antibody technology to other biotech and pharma companies.
  • See the IPO prospectus here.

Posted In: BriefsCovid-19BiotechNewsHealth CareFinancingIPOsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.